We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Petros Pharmaceuticals Inc is a men's health pharmaceutical company. It focuses on identifying, developing, acquiring, and commercializing innovative therapeutics for men's health issues including erectile dysfunction, peyronie's disease, hormone health and substance use disorders. The company's ope... Petros Pharmaceuticals Inc is a men's health pharmaceutical company. It focuses on identifying, developing, acquiring, and commercializing innovative therapeutics for men's health issues including erectile dysfunction, peyronie's disease, hormone health and substance use disorders. The company's operating segment includes Prescription Medications and Medical Devices. It generates maximum revenue from the Prescription Medications segment. The Prescription Medications segment consists primarily of operations related to Stendra, which is sold generally in the United States, and H100 for the treatment of Peyronie's disease. Show more
false 0001815903 0001815903 2024-01-08 2024-01-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED...
false 0001815903 0001815903 2023-12-29 2023-12-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED...
false 0001815903 0001815903 2023-12-21 2023-12-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED...
SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...
SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...
SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.04 | 2.83687943262 | 1.41 | 1.59 | 1.36 | 698036 | 1.50981059 | CS |
4 | -0.25 | -14.7058823529 | 1.7 | 1.75 | 1.3 | 900839 | 1.51013216 | CS |
12 | -0.05 | -3.33333333333 | 1.5 | 2.27 | 1.04 | 1106393 | 1.39871639 | CS |
26 | -0.11 | -7.05128205128 | 1.56 | 2.27 | 1.04 | 616991 | 1.40052974 | CS |
52 | 0 | 0 | 1.45 | 9.54 | 0.9172 | 1061797 | 3.82610512 | CS |
156 | -34.05 | -95.9154929577 | 35.5 | 52 | 0.9172 | 2159758 | 25.33617189 | CS |
260 | -16.55 | -91.9444444444 | 18 | 59.599 | 0.9172 | 1964064 | 25.42735505 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions